Increase of glucose and lactate output and decrease of fl ow by human anaphylatoxin C3a but not C5a in perfused rat liver
INTRODUCTION
Pyrogenic substances such as cell wall particles from yeast (zymosan) [1,2] and lipopolysaccharides from Gram negative bacteria [3] have been shown to increase glucose and lactate output and to reduce perfusion flow or increase portal pressure, respectively, in the perfused rat liver. Similar alterations were observed after infusion of heat-aggregated immunoglobulins which resemble immune complexes in their biological properties [4] . Rabbit serum that had been complement activated by incubation with zymosan was shown to induce the release of thromboxane from rabbit livers [5] . The complement fragments C3a and C5a have been reported to cause contraction of smooth muscle [6] and human C5a was shown to elicit vasoconstriction in the kidneys of Munich Wistar rats [7] .
It was the aim of this study to evaluate whether these peptides might affect the metabolism and the Correspondence address: G.P. Puschel, Institut fur Biochemie, Georg-August-Universitat, Humboldtallee 23, D-3400 Gottingen, FRO hemodynamics of the liver. Complement-activated human serum and the purified anaphylatoxin C3a but not C5a were found to increase glucose and lactate output and to decrease flow in the perfused rat liver.
MATERIALS AND METHODS

Materials
All chemicals were reagent grade and from commercial sources. The Merck glucose system was purchased from Merck (D-6100 Darmstadt). Lactate dehydrogenase and glutamic pyruvic transaminase were from Boehringer (D-6800 Mannheim). The thromboxane antagonist BM13505 was a gift of this company. f-Amino caproic acid and carboxypeptidase B were obtained from Sigma (D-S024 Deisenhofen). MERGETPA was purchased from Calbiochem (D-6000 Frankfurt) and polyethylene glycol 6000 (PEG) from Serva (D-6900 Heidelberg). CM-52 Cellulose was obtained from Whatman (UK-ME 14 2LE Kent) and Sephadex G50 fine from Pharmacia (D-7800 Freiburg). Dialysis tubing with a cut off of 3.5 kDa was bought from Reichelt (D-6900 Heidelberg).
Animals
Male Wistar rats (140-180 g, Winkelmann, D-4791 Borchen) were kept on a 12 h day-night rhythm, light from 7 a.m. to 7 p.m., with free access to water and food (standard rat diet, Ssniff, D-4770 Soest). All experiments were started between 9 and 10 a.m.
Isolation oj human C3a and C5a
Human C3a and C5a were purified using a modified method based on a previous brief description of the C5a purification [81. Human serum obtained from healthy blood donors through the transfusion service of the university hospital was activated with boiled yeast cells (zymosan) in the presence of 1 M taminocaproic acid for I h at 37°C. Ail subsequent steps were carried out at 0-4°C. The bulk of the proteins was precipitated by adding 10% (w/v) PEG and titrating the incubation mixture to pH 4.0 with 8 N HC1. Zymosan and precipitated proteins were removed by centrifugation at 27000 x g for 30 min. The supernatants were then frozen at -20°C overnight and the centrifugation repeated after thawing the sample the next morning. The clear supernatant was diluted about fivefold with 50 mM ammonium formate, pH 4.5, to reach a conductivity of about 10 mS/cm. This sample was applied to a CM-52 column that was equilibrated with the same buffer. The column was washed with 400 ml of the equilibration buffer and eluted with 800 ml of a linear NaCl gradient from 0 to 0.8 M in the same buffer (fig.l). C5a and C3a were detected in the eluate employing EL ISA procedures [8, 9] . The fractions with the highest contents of the respective peptides were pooled for further purification.
The C5a pool was lyophilized and redissolved in 8 ml of 25 mM Tris-HCl, pH 7.4. It was chromatographed on Sephadex G50 fine equilibrated with the same Tris-HCl buffer containing 154 mM NaCl which was also used for elution ( fig.l) . The C5a-containing fractions were pooled and stored at -20°C.
The C3a pool was dialyzed against 10 mM sodium-acetate, pH 5.0, using a dialysis tubing with a 3.5 kDa cutoff and applied to CM-52 cellulose equilibrated with the same buffer. The proteins were eluted with the equilibration buffer containing 0.6 M NaCl. The C3a-comaining fractions were pooled and stored at -20°C.
The purity of the C3a and C5a preparations was ascertained by standard SDS-polyacrylamide gel electrophoresis (SDS-PAGE) [10].
Antibodies against C3 and C5a
Monoclonal antibodies specific for C3a or C5a, respectively, were produced as described [8, 11] ; Fab fragments from the anti-C3a antibodies were obtained by papain-cleavage. They were purified by FPLC anion-exchange chromatography on Mono-Q [12] .
Liver perfusion
Rats were anaesthetized by intraperitoneal injection of pentobarbital (60 mg/kg body wt). The liver was perfused in situ as described previously [13] using an erythrocyte-free KrebsHenseleit bicarbonate buffer, which contained 5 mM glucose, 2 mM lactate and 0.2 mM pyruvate and was equilibrated with 95% 02/5% CO2 (v/v). After a preperfusion period of 30 min the experiment was started. At the times indicated purified C3a or C5a were infused. The flow was determined by quantitating the perfusate fractions collected at 1 min intervals.
Metabolite assays
Glucose was determined in the perfusate using a commercial test kit (Merck Glucose System) based on the glucose dehydrogenase method [14] . Lactate was measured in a combined optical test using lactate dehydrogenase and glutamic pyruvic transaminase [15] .
RESULTS
Purification of the anaphylatoxins
Chromatography of zymosan-activated human serum on CM-52 cellulose after acidic PEG precipitation resulted in a good separation of C3a and C5a. C5a co-eluted with the major protein fraction at 0.25 M NaCl; C3a eluted, separated from the major protein peak, at about 0.6 M NaCl (fig.lA) volume, 50 ml/h flow rate, 2.5 ml fractions).
peak ( fig.IB) . The peak fractions of C5a were pooled; the preparation contained 6 C5a/ml and one major contaminant, which migrated in the SDS-PAGE as a 69 kDa band and was assumed to be albumin. Rechromatography of the dialyzed C3a fractions on CM-52 cellulose in a small column ( fig.lC) yielded a C3a preparation that had a concentration of 35 p% C3a/ml and was free of contaminants detectable by SDS-PAGE.
Actions of C3a and C5a on liver metabolism and hemodynamics
In perfused rat livers infusion of human serum at a rate of about 7% of the perfusion flow for 2 min caused a slight increase in glucose and lactate output and a slight decrease in perfusion flow. Preincubation of the serum with zymosan for 1 h at 37°C led to a marked enhancement of these effects (not shown). .3A  vs fig.2A ).
Infusion of purified human
In the presence of MERGETPA infusion of about 0.4 fig C3a/ml for 30 s caused already maximal alterations, while the minimal concentration of C3a that was found to reduce flow and to increase lactate output was 0.08 /*g/ml. An increase in glucose output could still be observed at 0.04 ^g/ml (not shown).
Inhibition of the metabolic and hemodynamic actions of C3a
Preincubation The time course of the change of glucose output was not altered by BM13505; however, the lactate output remained increased until the end of the experiment (not shown).
DISCUSSION
This study showed that the purified human C3a anaphylatoxin, the activation peptide of the third component of complement, induced an increase in glucose and lactate outputs and a reduction in flow in perfused rat liver (figs 2A, 3A) . it further demonstrated that these actions could be antagonized by the Fab fragments of a C3a-specific monoclonal antibody (fig.3B). 
Mechanism of action of the anaphylatoxin C3a
The thromboxane antagonist BM13505 was found to interfere with the action of C3a on liver metabolism and hemodynamics (fig.4) . This indicates that the action of C3a was indirect, at least in part. The anaphylatoxin might cause a release of 86
